Vedolizumab response in inflammatory bowel disease. Two years of follow-up

Vedolizumab response in inflammatory bowel disease. Two years of follow-up

BACKGROUNDvedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab. METHODSthis was a retrospective study of inflammatory bowel disease (IBD) patients who received vedolizumab between 2016 and 2019. Response and remi...

Full description

Saved in:
Bibliographic Details
Published in:Revista española de enfermedades digestivas Vol. 112; no. 7; pp. 555 - 558
Main Authors: del Pino Bellido, Pilar, Belvis Jiménez, María, Castro Laria, Luisa, Maldonado Pérez, María Belén, Sáez Díaz, Antonia, Caunedo Álvarez, Ángel, Argüelles-Arias, Federico
Format: Journal Article
Language:English
Published: 01-01-2020
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUNDvedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab. METHODSthis was a retrospective study of inflammatory bowel disease (IBD) patients who received vedolizumab between 2016 and 2019. Response and remission rates were analyzed at three, six, 12, 18 and 24 months after induction. RESULTSfifty-five patients were included. Clinical remission rates in CD and UC at three, six, 12, 18 and 24 months were 19.35 %, 26.67 %, 30.43 %, 30 %, 38.89 % and 29.17 %, 26.09 %, 19.05 %, 26.67 % and 20 %, respectively. CONCLUSIONSvedolizumab is effective for induction and maintenance of clinical remission, both in Crohn's disease and ulcerative colitis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1130-0108
DOI:10.17235/reed.2020.7130/2020